TY - JOUR
T1 - Beyond R-CHOP and the IPI in large-cell lymphoma
T2 - Molecular markers as an opportunity for stratification
AU - Westin, Jason R.
AU - Fayad, Luis E.
N1 - Copyright:
Copyright 2012 Elsevier B.V., All rights reserved.
PY - 2009
Y1 - 2009
N2 - Diffuse large B-cell lymphoma (DLBCL) is the most common type of lymphoma in Western countries and represents a heterogeneous group of diseases. Historically, the disease has been stratified based solely on clinical prognostic factors, such as those that make up the International Prognostic Index (IPI). In the past decade, many advances have been made in understanding the biology of DLBCL, including clinical aspects, gene expression profiling, and microRNA. These evaluations have revealed several distinct subtypes with differing responses to therapy and different long-term outcomes, but the standard initial therapy for DLBCL continues to use regimens like R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone) regardless of the disease subtype. Despite improvements in the diagnosis and treatment of this condition, nearly one third of patients die of their disease. This article reviews the history of DLBCL, prognostic factors, therapy, and possible future directions.
AB - Diffuse large B-cell lymphoma (DLBCL) is the most common type of lymphoma in Western countries and represents a heterogeneous group of diseases. Historically, the disease has been stratified based solely on clinical prognostic factors, such as those that make up the International Prognostic Index (IPI). In the past decade, many advances have been made in understanding the biology of DLBCL, including clinical aspects, gene expression profiling, and microRNA. These evaluations have revealed several distinct subtypes with differing responses to therapy and different long-term outcomes, but the standard initial therapy for DLBCL continues to use regimens like R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone) regardless of the disease subtype. Despite improvements in the diagnosis and treatment of this condition, nearly one third of patients die of their disease. This article reviews the history of DLBCL, prognostic factors, therapy, and possible future directions.
UR - http://www.scopus.com/inward/record.url?scp=70349730030&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=70349730030&partnerID=8YFLogxK
U2 - 10.1007/s11899-009-0029-y
DO - 10.1007/s11899-009-0029-y
M3 - Review article
C2 - 20425411
AN - SCOPUS:70349730030
SN - 1558-8211
VL - 4
SP - 218
EP - 224
JO - Current hematologic malignancy reports
JF - Current hematologic malignancy reports
IS - 4
ER -